Topic

Gilead Sciences

3 stories related to this topic, newest first.

Gilead’s Phase 3 IDEAL Study Shows Livdelzi Superior to Placebo on ALP Normalization in Mildly Elevated PBC Patients

Benzinga

science19 days ago

Gilead’s Phase 3 IDEAL Study Shows Livdelzi Superior to Placebo on ALP Normalization in Mildly Elevated PBC Patients

Gilead Sciences released Phase 3 IDEAL study data showing Livdelzi achieved statistically significant ALP normalization versus placebo after 52 weeks in patients with inadequately controlled primary biliary cholangitis.

1 source

Biotech Developments Include Duchenne Drug Class, Gilead Acquisitions and Industry Updates

Substrate placeholder — needs review

science74 days ago

Biotech Developments Include Duchenne Drug Class, Gilead Acquisitions and Industry Updates

A class of drugs for Duchenne muscular dystrophy has drawn attention in recent discussions. Gilead Sciences continues its series of mergers and acquisitions in the biotech sector. Additional news covers ongoing advancements and regulatory matters in biotechnology.

1 source

Gilead Sciences Acquires German Biotech Tubulis for Over $3 Billion

Substrate placeholder — needs review

science75 days ago

Gilead Sciences Acquires German Biotech Tubulis for Over $3 Billion

Gilead Sciences announced the acquisition of Tubulis, a German biotechnology company, for more than $3 billion. The deal aims to expand Gilead's oncology drug development pipeline. Tubulis specializes in antibody-drug conjugates for cancer treatments.

1 source